ERBB3 and breast carcinoma: Seven clinical trials are in progress to evaluate HER3-DXd for the treatment of patients with breast cancer or NSCLC [17]; these are tumors that are known to overexpress HER3 and in which HER3 mutations have been reported [1, 3, 4].